Vertex and CRISPR Therapeutics: The EMA Granted PRIME Designation to CTX001. Read Also: Cassava Sciences Encouraging News

Today’s Highlights April 26, 2021

Vertex and CRISPR Granted PRIME Designation from the EMA for CTX001
Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (This content is for paid subscribers.

Please click here to subscribe or here to log in.

Today’s Highlights
Cassava Sciences (SAVA), CRISPR Therapeutics (CRSP), Vertex Pharmaceuticals (VRTX)
April 26, 2021

Tweet Pin It

Other Articles

Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection

January 20, 2026 0

Two Companies: 1. FDA Extended Review for Eli Lilly’s Oral Obesity Drug, Orforglipron. 2. Wall Street is Bullish on Spyre Therapeutics

January 16, 2026 0

Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease

January 13, 2026 0

AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

January 12, 2026 0

Search ProhostBiotech

Popular Links
Aerie Pharmaceuticals (AERI) Agenus (AGEN) Alnylam Pharmaceuticals (ALNY) Amgen (AMGN) Array BioPharma (ARRY) AstraZeneca Plc (AZN) Bellicum Pharmaceuticals Inc (BLCM) Bristol-Myers Squibb (BMY) Celgene (CELG) Celldex Therapeutics (CLDX) Cellectis (CLLS) Celyad (CYAD) Compugen (CGEN) CRISPR Therapeutics (CRSP) CytomX Therapeutics Inc (CTMX) Editas Medicine Inc (EDIT) Enanta Pharmaceuticals (ENTA) Exelixis (EXEL) Gilead Sciences (GILD) Halozyme Therapeutics (HALO) Illumina (ILMN) ImmunoGen (IMGN) Incyte (INCY) Innoviva (INVA) Intellia Therapeutics (NTLA) Ionis Pharmaceuticals Inc (IONS) Karyopharm Therapeutics Inc (KPTI) Merck (MRK) Moderna Inc (MRNA) Nektar Therapeutics (NKTR) Neurocrine Biosciences (NBIX) Novartis (NVS) Portola Pharmaceuticals Inc (PTLA) PTC Therapeutics (PTCT) Regeneron Pharmaceuticals (REGN) Regenxbio (RGNX) Rhythm Pharmaceuticals Inc (RYTM) Sangamo Therapeutics Inc (SGMO) Sarepta Therapeutics (SRPT) Seagen Inc (SGEN) Spark Therapeutics Theravance Biopharma (TBPH) Vertex Pharmaceuticals (VRTX) Xoma (XOMA)

Recent

ProhostBiotech Archive
ProhostBiotech Archive
Sign Up for Weekly Emails
First Name

Last Name

Email address:

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
© 2014 Prohost Biotech. All rights reserved.
Privacy Policy | Cancellation Policy | Forward Looking Statement

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

Exclusive Market Insight

& Scientific analysis

Vertex and CRISPR Therapeutics: The EMA Granted PRIME Designation to CTX001. Read Also: Cassava Sciences Encouraging News